Option Care Health Selected By Krystal Biotech As Part Of A Limited Distribution Specialty Pharmacy Network For VYJUVEK
Portfolio Pulse from Benzinga Newsdesk
Option Care Health (OPCH) has been selected by Krystal Biotech (KRYS) as part of a limited distribution specialty pharmacy network for VYJUVEK, an FDA-approved topical treatment for Dystrophic Epidermolysis Bullosa (DEB). Option Care Health will collaborate with Amedisys to administer the treatment in home settings.
May 23, 2023 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech (KRYS) has selected Option Care Health (OPCH) for the distribution of its FDA-approved DEB treatment, VYJUVEK, and will collaborate with Amedisys for home administration.
Krystal Biotech's selection of Option Care Health for the distribution of VYJUVEK is a positive development for the company, as it ensures a reliable distribution network for their product. The collaboration with Amedisys for home administration further expands the accessibility of the treatment, which is expected to have a positive short-term impact on KRYS's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Option Care Health (OPCH) has been chosen by Krystal Biotech (KRYS) for the distribution of VYJUVEK, a DEB treatment, and will collaborate with Amedisys for home administration.
Option Care Health being selected by Krystal Biotech for the distribution of VYJUVEK is a positive development for the company, as it expands their product offerings and strengthens their partnership with Amedisys. This collaboration is expected to have a positive short-term impact on OPCH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100